Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs

Therapeutic Drug Monitoring

Volumn 30, Issue 2, 2008, Pages 173-180

  Anderson, Gail D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Antiepileptic drugs; Pharmacogenetics; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

BIOLOGICAL MARKER; CARBAMAZEPINE; CLONAZEPAM; COLCHICINE; CYCLOSPORIN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 ISOENZYME; DIGOXIN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; GLYCOPROTEIN P; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; STIRIPENTOL; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VINBLASTINE; ZONISAMIDE;

BIOEQUIVALENCE; CLINICAL MEDICINE; CLINICAL STUDY; COMPREHENSION; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE CONTROL; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; EPILEPTIC STATE; EXPERIMENTAL STUDY; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETICS; HISTORY; HUMAN; MENTAL DISEASE; MIGRAINE; MYOCLONUS EPILEPSY; NONHUMAN; PAIN; PATIENT COMPLIANCE; PATIENT SAFETY; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACOKINETICS; POPULATION RESEARCH; PREDICTION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK; RISK BENEFIT ANALYSIS; SEIZURE;

ANTICONVULSANTS; BIOLOGICAL AVAILABILITY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG MONITORING; DRUGS, GENERIC; EPILEPSY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; THERAPEUTIC EQUIVALENCY;

EID: 42049090602     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318167d11b     Document Type: Conference Paper

References (102)

1. Schmidt D, Einicke I, Haenel F. The influence of seizure type on the efficacy of plasma concentrations of phenytoin, phenobarbital and carbamazepine. Arch Neurol. 1986;43:263-265.
2. Eadie MJ. Therapeutic drug monitoring - antiepileptic drugs. Br J Clin Pharmacol. 1998;46:185-193.
3. Johannessen SI. Plasma drug concentration monitoring of anticonvulsants. Practical guidelines. CNS Drugs. 1997;7:349-365.
4. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet. 2000;38:191-204.
5. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003;25:347-363.
6. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45:1061-1075.
7. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989-1008.
8. Anderson GD. Children versus adults: pharmacokinetic and adverseeffect differences. Epilepsia. 2002;43(Suppl 3):53-59.
9. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet. 2007;46:209-219.
10. Buchthal F, Svensmark O, Schiller PJ. Clinical and electroencephalographic correlations with serum levels of diphenylhydantoin. Arch Neurol. 1960;2:624-630.
11. Lund L. Effects of phenytoin in patients with epilepsy in relation to its concentration in plasma. In: Davis DS, Prichard BNC, eds. Biological Effects of Drugs in Relation to Their Plasma Concentrations. Baltimore: University Park Press; 1972:227-238.
12. Kutt H, Winters W, Kokenge R, et al. Diphenylhydantoin metabolism, blood levels, and toxicity. Arch Neurol. 1964;11:642-648.
13. Feely M, O'Callagan M, Duggan B, et al. Phenobarbitone in previously untreated epilepsy. J Neurol Neurosurg Psychiatry. 1980;43:365-368.
14. Haerer AF, Buchanan RA, Wiygul FM. Ethosuximide blood levels in epileptics. J Clin Pharmacol. 1970;10:370-374.
15. Eadie MJ, Tyrer JH. Anticonvulsant Therapy. Pharmacological Basis of Practice, 2nd ed. Edinburgh: Churchill Livingstone; 1980.
16. Friel PN, Ojemann GA, Rapport RL, et al. Human brain phenytoin: correlation with unbound and total serum concentrations. Epilepsy Res. 1989;3:82-85.
17. Harvey CD, Sherwin AL, Van Der Kleijn E. Distribution of anticonvulsant drugs in gray and white matter of human brain. Can J Neurol Sci. 1977;4:89-92.
18. Houghton GW, Richens A, Toseland PA, et al. Brain concentrations of phenytoin, phenobarbital and primidone in epileptic patients. Eur J Clin Pharmacol. 1975;9:73-78.
19. Paulson OB, Gyory A, Hertz MM. Blood-brain barrier transfer and cerebral uptake of antiepileptic drugs. Clin Pharmacol Ther. 1982;32:466-477.
20. Rambeck B, Schnabel R, May T, et al. Postmortem concentrations of phenobarbital, carbamazepine, and its metabolite carbamazepine-10,11-epoxide in different regions of the brain and in serum: analysis of autoptic specimens from 51 epileptic patients. Ther Drug Monit. 1993;15:91-98.
21. Scheyer RD, During MJ, Hochholzer JM, et al. Phenytoin concentrations in the human brain: an in vivo microdialysis study. Epilepsy Res. 1994;18:227-232.
22. Sherwin AL, Eisen AA, Sagolowski CD. Anticonvulsant drugs in human epileptogenic brain. Arch Neurol. 1973;29:73-77.
23. Vajda F, Williams FM, Davidson S, et al. Human brain, cerebrospinal fluid, and plasma concentrations of diphenylhydantoin and phenobarbital. Clin Pharmacol Ther. 1974;15:597-603.
24. Scheyer RD, During MJ, Spencer DD, et al. Measurement of carbamazepine and carbamazepine epoxide in the human brain using in vivo microdialysis. Neurology. 1994;44:1469-1472.
25. Schnabel R, Rambeck B, May TW, et al. Concentrations of carbamazepine and carbamazepine-10, 11-epoxide in serum, brain tumors and paratumorous cortex: a prospective study of 37 neurosurgically treated epileptic patients. Eur Neurol. 1994;34:213-220.
26. Shen DD, Ojemann GA, Rapport RL, et al. Low and variable presence of valproic acid in human brain. Neurology. 1992;42:582-585.
27. Adab N. Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful? CNS Drugs. 2006;20:791-800.
28. Johannessen SI. Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs. Ther Drug Monit. 2005;27:710-713.
29. Bialer M, Twyman RE, White HS. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav. 2004;5:866-872.
30. Nuwer M, Browne T, Dodson W, et al. Generic substitution for antiepileptic drugs. Neurology. 1990;40:1647-1651.
31. Liow K, Barkley GL, Pollard JR, et al. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology. 2007;68:1249-1250.
32. Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia. 2007;48:1825-1832.
33. Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
34. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22:11-23.
35. Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model List of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265-278.
36. Meyer MC, Straughn AB, Jarvi EJ, et al. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res. 1992;9:1612-1616.
37. Leppik IE. Compliance during treatment of epilepsy. Epilepsia. 1988;29(Suppl 2):S79-84.
38. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277.
39. Barry E, Hauser WA. Status epilepticus and antiepileptic medication levels. Neurology. 1994;44:47-50.
40. Specht U, Elsner H, May TW, et al. Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav. 2003;4:487-495.
41. Knott C, Bateman M, Reynolds F. Do saliva concentrations predict plasma unbound theophylline concentrations? A problem re-examined. Br J Clin Pharmacol. 1984;17:9-14.
42. Knott C, Reynolds F. The place of saliva in antiepileptic drug monitoring. Ther Drug Monit. 1984;6:35-41.
43. Liu H, Delgado MR. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet. 1999;36:453-470.
44. Mecarelli O, Li Voti P, Pro S, et al. Saliva and serum levetiracetam concentrations in patients with epilepsy. Ther Drug Monit. 2007;29:313-318.
45. Malone SA, Eadie MJ, Addison RS, et al. Monitoring salivary lamotrigine concentrations. J Clin Neurosci. 2006;13:902-907.
46. Jones MD, Ryan M, Miles MV, et al. Stability of salivary concentrations of the newer antiepileptic drugs in the postal system. Ther Drug Monit. 2005;27:576-579.
47. Aminoff MJ, Simon RP. Status epilepticus. Causes, clinical features and consequences in 98 patients. Am J Med. 1980;69:657-666.
48. Dunn DW. Status epilepticus in children: etiology, clinical features, and outcome. J Child Neurol. 1988;3:167-173.
49. Piquette-Miller M, Grant DM. The art and science of personalized medicine. Clin Pharmacol Ther. 2007;81:311-315.
50. Sisodiya S, Cross JH, Blumcke I, et al. Genetics of epilepsy: Epilepsy Research Foundation workshop report. Epileptic Disord. 2007;9:194-236.
51. Mamiya K, Hadama A, Yukawa E, et al. CYP2C19 polymorphism effect on phenobarbitone. Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. Eur J Clin Pharmacol. 2000;55:821-825.
52. Hadama A, Ieiri I, Morita T, et al. P-hydroxylation of phenobarbital: relationship to (S)-mephenytoin hydroxylation (CYP2C19) polymorphism. Ther Drug Monit. 2001;23:115-118.
53. Brandolese R, Scordo MG, Spina E, et al. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther. 2001;70:391-394.
54. Ninomiya H, Mamiya K, Matsuo S, et al. Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. Ther Drug Monit. 2000;22:230-232.
55. Odani A, Hashimoto Y, Otsuki Y, et al. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther. 1997;62:287-292.
56. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48:1223-1244.
57. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest. 1988;82:1826-1832.
58. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenetics and Genomics. 2006;16:297-306.
59. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.
60. Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48:1015-1018.
61. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006;7:813-818.
62. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 2006;6:265-268.
63. Glauser TA. Idiosyncratic reactions: new methods of identifying highrisk patients. Epilepsia. 2000;41(Suppl 8):S16-29.
64. Schmidt D, Loscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia. 2005;46:858-877.
65. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. Epilepsia. 2005;46:224-235.
66. Anderson GD, Shen DD. Where is the evidence that P-glycoprotein limits brain uptake of antiepileptic drug and contributes to drug resistance in epilepsy? Epilepsia. In press.
67. Drion N, Lemaire M, Lefauconnier JM, et al. Role of P-glycoprotein in the blood-brain transport of colchicine and vinblastine. J Neurochem. 1996;67:1688-1693.
68. Potschka H, Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia. 2001;42:1231-1240.
69. Potschka H, Fedrowitz M, Loscher W. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport. 2001;12:3557-3560.
70. Potschka H, Fedrowitz M, Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence from microdialysis experiments in rats. Neurosci Lett. 2002;327:173-176.
71. Harrison A, Betts A, Fenner K, et al. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4- (morpholinocarbonyl)-perhydr o-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations. Drug Metab Dispos. 2004;32:197-204.
72. Onishi S, Ohki Y, Nishimura Y, et al. Distribution of phenobarbital in serum, brain and other organs from pediatric patients. Dev Pharmacol Ther. 1984;7:153-159.
73. Berkovic SF, Mulley JC, Scheffer IE, et al. Human epilepsies: interaction of genetic and acquired factors. Trends Neurosci. 2006;29:391-397.
74. Mulley JC, Scheffer IE, Petrou S, et al. SCN1A mutations and epilepsy. Hum Mutat. 2005;25:535-542.
75. Fujiwara T. Clinical spectrum of mutations in SCN1A gene: severe myoclonic epilepsy in infancy and related epilepsies. Epilepsy Res. 2006;70(Suppl 1):S223-230.
76. Yu FH, Mantegazza M, Westenbroek RE, et al. Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006;9:1142-1149.
77. Kalume F, Yu FH, Westenbroek RE, et al. Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy. J Neurosci. 2007;27:11065-11074.
78. Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia. 1999;40:1471-1483.
79. Braga MF, Aroniadou-Anderjaska V, Post RM, et al. Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. Neuropharmacology. 2002;42:522-529.
80. Bertrand D, Picard F, Le Hellard S, et al. How mutations in the nAChRs can cause ADNFLE epilepsy. Epilepsia. 2002;43(Suppl 5):112-122.
81. Marini C, Guerrini R. The role of the nicotinic acetylcholine receptors in sleep-related epilepsy. Biochem Pharmacol. 2007;74:1308-1314.
82. Ortells MO, Barrantes GE. Molecular modelling of the interactions of carbamazepine and a nicotinic receptor involved in the autosomal dominant nocturnal frontal lobe epilepsy. Br J Pharmacol. 2002;136:883-895.
83. Hirose S, Mitsudome A, Okada M, et al. Genetics of idiopathic epilepsies. Epilepsia. 2005;46(suppl 1):38-43.
84. Main MJ, Cryan JE, Dupere JR, et al. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol. 2000;58:253-262.
85. Wickenden AD, Yu W, Zou A, et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol. 2000;58:591-600.
86. Blackburn-Munro G, Dalby-Brown W, Mirza NR, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Reviews. 2005;11:1-20.
87. Budavari S. The Merck Index, 13th ed. Whitehouse Station, NJ: Merck & Co, Inc; 1996.
88. Anderson GD, Miller JW. Benzodiazepines: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:187-205.
89. Pisani F, Perucca E, Bialer M. Ethosuximide: chemistry, biotransformation, pharmacokinetics and drug interactions. In: Levy RH, Mattson RH, Meldrun BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:646-651.
90. Kucharczyk N. Felbamate. Chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York: Raven Press; 1995:799-806.
91. Vajda FJE. Gabapentin: chemistry, biotransformation, pharmacokinetics, and interactions. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippencott Williams & Wilkins; 2002:335-343.
92. Dickins M, Sawyer DA, Moreley TJ, et al. Lamotrigine: chemistry and biotransformation. In: Levy RH, Mattson RH, Meldrun BS, eds. Antiepileptic Drugs, 5th ed. New York: Raven Press; 1995:871-875.
93. Patsalos PN. Levetiracetam: chemistry, biotransformation, pharmacokinetics and drug interactions. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:428-432.
94. Bialer M. Oxcarbazepine. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:459-465.
95. Ben-Menachem E. Pregablin. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins; 2002:901-905.
96. Fincham RW. Primidone. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:621-635.
97. Sommerville KW, Collins SD. Tiagabine. Chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antipileptic Drugs. Philadelphia: Lippincott Williams & Wilkins; 2002:681-690.
98. Doose DR, Streeter AJ. Topiramate: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:727-734.
99. Shah J, Shellenberger K, Canafax DM. Zonisamide: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al, eds. Antiepileptic Drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002:873-879.
100. Schinkel AH, Smit JJ, van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 1994;77:491-502.
101. Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest. 1995;96:1698-1705.
102. Sills GJ, Kwan P, Butler E, et al. P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. Epilepsy Behav. 2002;3:427-432.